Clinical trial
A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell…
NCT00389051 · SymBio Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00389051 |
|---|---|
| Title | A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma |
| Official title | A Multicenter, Open Study to Assess the Tolerability, Pharmacokinetics and Antitumor Effect of Bendamustine Hydrochloride (SyB L-0501: 90 or 120 mg/m2/Day) Administered Intravenously for Two Days in Patients With Indolent Lymphoma |
| Lead sponsor | SymBio Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | bendamustine hydrochloride |
| Enrollment | 9 |
| Start date | Oct 31, 2006 |
| Primary completion | Jul 5, 2007 |
| Completion | Oct 26, 2007 |
| First posted | Oct 17, 2006 |
| Last update posted | Oct 22, 2020 |
| Countries | Japan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: